| # | Drug | Count |
|---|---|---|
| 0 | TACROLIMUS | 19 |
| 1 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 19 |
| 2 | TACROLIMUS OINTMENT 0.1% | 19 |
| 3 | GOSERELIN | 17 |
| 4 | FULVESTRANT | 12 |
| 5 | FUROSEMIDE | 12 |
| 6 | ALLOPURINOL | 11 |
| 7 | BICALUTAMIDE | 11 |
| 8 | DOCETAXEL | 11 |
| 9 | DOCETAXEL ANHYDROUS | 11 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TEBENTAFUSP | 1 | 0.0017 |
| 1 | PRALATREXATE | 1 | 0.0015 |
| 2 | GOSERELIN | 17 | 0.0013 |
| 3 | IDARUBICIN HYDROCHLORIDE | 1 | 0.0009 |
| 4 | BICALUTAMIDE | 11 | 0.0007 |
| 5 | PLERIXAFOR | 1 | 0.0007 |
| 6 | LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN | 9 | 0.0007 |
| 7 | ROMIDEPSIN | 1 | 0.0006 |
| 8 | GLUTATHIONE | 1 | 0.0006 |
| 9 | VINBLASTINE SULFATE | 1 | 0.0005 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 22 |
| 1 | Kinase Inhibitor [EPC] | 22 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 18 |
| 3 | Aromatase Inhibitor [EPC] | 13 |
| 4 | Estrogen Receptor Antagonist [EPC] | 12 |
| 5 | HER2/neu Receptor Antagonist [EPC] | 12 |
| 6 | Loop Diuretic [EPC] | 12 |
| 7 | Microtubule Inhibitor [EPC] | 12 |
| 8 | Androgen Receptor Inhibitor [EPC] | 11 |
| 9 | Xanthine Oxidase Inhibitor [EPC] | 11 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 1 | 0.0017 |
| 1 | Hematopoietic Stem Cell Mobilizer [EPC] | 1 | 0.0007 |
| 2 | Radioligand Therapeutic Agent [EPC] | 9 | 0.0007 |
| 3 | Estrogen Receptor Antagonist [EPC] | 12 | 0.0003 |
| 4 | Hedgehog Pathway Inhibitor [EPC] | 2 | 0.0002 |
| 5 | HER2/neu Receptor Antagonist [EPC] | 12 | 0.0002 |
| 6 | Androgen Receptor Inhibitor [EPC] | 11 | 0.0001 |
| 7 | Programmed Death Ligand-1 Blocker [EPC] | 3 | 0.0001 |
| 8 | Aromatase Inhibitor [EPC] | 13 | 0.0001 |
| 9 | Provitamin D2 Compound [EPC] | 3 | 0.0001 |